A5011780722- Drug-Induced Hepatotoxicity and Protection
- Pharmacogenetics and Drug Metabolism
- Liver physiology and pathology
- Liver Disease Diagnosis and Treatment
- Liver Diseases and Immunity
- Poisoning and overdose treatments
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2024
Instituto de Investigación Biomédica de Málaga
2022-2024
Universidad de Málaga
2022-2024
Andalusian Centre for Nanomedicine and Biotechnology
2023
Abstract Background & aims Idiosyncratic drug‐induced liver injury (DILI) with autoimmune features is a condition laboratory and histological characteristics similar to those of idiopathic hepatitis (AIH), which despite being increasingly reported, remains largely undefined. We aimed describe in‐depth the this entity in large series patients from two prospective DILI registries. Methods cases collected Spanish Registry Latin American Network were compared without an independent cohort...
The late event onset of a fraction idiosyncratic drug-induced liver injury (DILI) cases and the link observed by genome-wide association studies (GWASs) certain human leucocyte antigen (HLA) alleles with DILI due to specific drugs support crucial role immune system (both innate adaptive) in pathogenesis DILI. Recent advances both flow mass cytometry have allowed profiling all major cell types given sample. Therefore, determining lymphocyte populations samples from patients would facilitate...
<title>Abstract</title> Idiosyncratic drug-induced liver injury (DILI) is a complex and unpredictable event caused by different drugs, herbal, dietary supplements. The early identification of human hepatotoxicity at the preclinical stages remains major challenge, in which selection validated <italic>in vitro</italic> systems test drugs has significant impact. This systematic review aims to analyse compounds used assays establish unified list DILI positive negative control for validation...